Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
mdxhealth logo — Molecular Diagnostic Solutions for Prostate Cancer

mdxhealth

Molecular Diagnostic Solutions for Prostate Cancer

Founded 2003 United States Irvine, United States 262 employees Post-IPO Equity Total: $118.67M Biotechnology, Health Care +1

General Information

Company Name mdxhealth
Founded Year 2003
Location United States Irvine, United States
Founders / Decision Makers
Team member
Employees 262
Industries Biotechnology, Health Care, Medical Devices
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with mdxhealth. To contact mdxhealth, visit mdxhealth.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does mdxhealth compare?

A PDF of mdxhealth and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting mdxhealth soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About mdxhealth

Mdxhealth is a multinational healthcare company focusing on providing actionable molecular diagnostic information to customize the diagnosis and treatment of cancer. Utilizing proprietary genetic, epigenetic (methylation), and other molecular technologies, the company offers tests that aid physicians in diagnosing urologic cancers, forecasting recurrence risk, and anticipating the response to specific therapies. Mdxhealth was established in 2003 and has its European headquarters in Herstal, Belgium, with laboratory operations in Nijmegen, the Netherlands. Its US headquarters and laboratory operations are based in Irvine, California. The company operates in the biotechnology sector. The latest investment in the company amounted to $37.00M, in the form of a Post-IPO Equity investment on 03 February 2023. The specific investors involved in this latest funding round have not been disclosed.

Business keywords: Molecular Diagnostics, Cancer Diagnosis, Prostate Cancer, Genetic Testing, Epigenetic Testing, Pharmaceutical Products, Diagnostic Products, Next Generation Sequencing, Personalized Medicine, Cancer Treatment, Multinational Company, Clinical Laboratories

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $37.00M -
03 Feb 2023
Post IPO Debt $35.00M 1
Innovatus Capital Partners
Innovatus Capital Partners
02 Aug 2022
Post IPO Equity $14.00M 1
MVM Life Science Partners
27 Apr 2020
Post IPO Equity €9.00M -
27 Sep 2019
Grant €71.43K 1
EASME - EU Executive Agency for SMEs
01 Dec 2018
Post IPO Equity $23.60M 3
Valiance Advisors
Valiance Advisors, Petercam +1
25 Jun 2013
Post IPO Equity Undisclosed 1
IDInvest Partners
IDInvest Partners
02 Dec 2008

mdxhealth Alternatives & Competitors

View All Alternatives
mdxhealth vs
Dhiti Omics
Dhiti Omics India

Precision Molecular Diagnostics & Genetic Testing

Seed
15 employees
Biotechnology, Health Care
Compare mdxhealth vs Dhiti Omics
mdxhealth vs
Biocept, Inc.
Biocept, Inc. United States

Helping physicians improve outcomes for metastatic cancer patients by delivering advanced diagnostic...

Post-IPO Equity
49 employees
Biotechnology, Health Care
Compare mdxhealth vs Biocept, Inc.
mdxhealth vs
Agendia
Agendia United States

MammaPrint® + BluePrint® provides you with actionable insights throughout your patient’s breast canc...

Private Equity
209 employees
Biotechnology, Health Care
Also compare with: mdxhealth vs Beacon Biomedical Beacon Biomedical mdxhealth vs Genomtec SA Genomtec SA View all alternatives

FAQ About mdxhealth

Molecular Diagnostic Solutions for Prostate Cancer
mdxhealth was founded in 2003.
mdxhealth is headquartered in Irvine, United States.
mdxhealth operates in Biotechnology, Health Care and Medical Devices. Its work centres on Molecular Diagnostics, Cancer Diagnosis, Prostate Cancer and Genetic Testing.
mdxhealth has approximately 262 employees.
mdxhealth has completed 7 funding rounds, raising a total of $118.67M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to mdxhealth include Dhiti Omics, Biocept, Inc. , Agendia, Metamark Genetics, Beacon Biomedical. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
mdxhealth and Dhiti Omics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for mdxhealth, https://bouncewatch.com/company/mdxhealth, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout